When should single fraction SBRT be offered for peripheral NSCLC?

Now that RTOG 0915 shows 5 year data with no difference in OS, DFS, and toxicity, should single tx be routinely offered? Are there specific patient and tumor types that are most appropriate?

3 Answers

Mednet MemberInvited Expert

Radiation Oncology · Cleveland Clinic

Answered on

Based on the updated results of RTOG 0915 single fraction radiation to 34 Gy in 1 fraction is reasonable to offer to any patient with a peripheral stage I NSCLC < 5cm (limited single institution data from Germany and Japan shows safety and efficacy even for large lesions).

While RTOG 0915 does inclu...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert

Radiation Oncology · Mayo Clinic

Answered on

I would also add that I think 34/1 is a "reasonable" regimen, but not the standard of care. The RTOG 0915 was a phase 2 study powered to detect toxicity endpoints between 2 regimens in routine use, but not the RTOG standard of 54/3. The study was intended to set the stage for a phase 3 study of the ...

Join for free or sign in to see the full answer

Mednet Member

Radiation Oncology · Jacob E Locke MD PA

Answered on · Updated on

Facing this problem with a patient today, planning on 1 instead of 3 fraction regimen. Any rib dosimetry you can share? Presumably one should be "far" enough away i.e., well into the parenchyma, such that it is a nonfactor.

Join for free or sign in to see the full answer